Is Alzheimer’s Disease Genetic?

Only three percent of people who develop Alzheimer's inherit a rare, genetic early-onset form of the disease. But sussing out its genetic triggers could help to yield treatments for everyone.

Researchers have identified a set of genes that lead to Alzheimer’s disease by studying a small patient group with a rare, inherited, early-onset type of the disease.  Only about 3% of all Alzheimer’s patients are in this subgroup in which pronounced genetic factors cause the disease. Dr. Leonard Guarente, who studies aging at MIT, says that leveraging what is learned from this select 3% may help to yield treatments for everyone with the disease.

"We can’t really do anything about our genes," says Guarente, "but genetics clues us in on what the players are that are important in a disease."  Knowing these players is a step toward more effective treatments, he says.  Three of the genes that have a role in Alzheimer’s disease are:

  • Amyloid precursor protein (APP), which encodes a protein that causes the amyloid beta plaques and toxic substances that poison the brain, says Dr. Guarente. 
  • Presenilin, which is the enzyme that cuts the APP protein into pieces, allowing the amyloid beta bits to break free and poison the brain.  
  • ApoE4, which is an allele of the ApoE gene that has been linked to causing amyloid and increasing the chance of getting Alzheimer’s disease.  There are "more people with Alzheimer’s disease partially because they have an ApoE4 gene than with any other genetic risk factor," says Dr. Samuel Gandy, who studies Alzheimer’s disease at Mount Sinai Hospital. Yet, why this allele in particular raises risk remains to be discovered. 

    Alzheimer’s disease often occurs in parallel with other diseases and disorders, and understanding these genes has, in part, helped to explained the concurrence. "Patients with Down Syndrome which have a definite genetic abnormality, all of them will have at least pathological Alzheimer’s disease," says Dr. Juan Troncoso, director of the Brain Resource Center at Johns Hopkins Hospital.  The link, he says, is the APP gene, which resides on the segment of the same chromosome that is extra in patients with Down Syndrome.  Such a finding "supports the hypothesis that the APP and the amyloid is a triggering factor in [Alzheimer’s] disease," he says.

    The views expressed here are solely those of the participants, and do not represent the views of Big Think or its sponsors.

    LinkedIn meets Tinder in this mindful networking app

    Swipe right to make the connections that could change your career.

    Getty Images
    Swipe right. Match. Meet over coffee or set up a call.

    No, we aren't talking about Tinder. Introducing Shapr, a free app that helps people with synergistic professional goals and skill sets easily meet and collaborate.

    Keep reading Show less

    Brain study finds circuits that may help you keep your cool

    Research by neuroscientists at MIT's Picower Institute for Learning and Memory helps explain how the brain regulates arousal.

    Photo by CHARLY TRIBALLEAU / AFP/ Getty Images
    Mind & Brain

    MIT News

    The big day has come: You are taking your road test to get your driver's license. As you start your mom's car with a stern-faced evaluator in the passenger seat, you know you'll need to be alert but not so excited that you make mistakes. Even if you are simultaneously sleep-deprived and full of nervous energy, you need your brain to moderate your level of arousal so that you do your best.

    Keep reading Show less

    34 years ago, a KGB defector chillingly predicted modern America

    A disturbing interview given by a KGB defector in 1984 describes America of today and outlines four stages of mass brainwashing used by the KGB.

    Politics & Current Affairs
    • Bezmenov described this process as "a great brainwashing" which has four basic stages.
    • The first stage is called "demoralization" which takes from 15 to 20 years to achieve.
    • According to the former KGB agent, that is the minimum number of years it takes to re-educate one generation of students that is normally exposed to the ideology of its country.
    Keep reading Show less

    How pharmaceutical companies game the patent system

    When these companies compete, in the current system, the people lose.

    Top Video Splash
    • When a company reaches the top of the ladder, they typically kick it away so that others cannot climb up on it. The aim? So that another company can't compete.
    • When this happens in the pharmaceutical world, certain companies stay at the top of the ladder, through broadly-protected patents, at the cost of everyday people benefitting from increased competition.
    • Since companies have worked out how to legally game the system, Amin argues we need to get rid of this "one size fits all" system, which treats product innovation — "tweaks" — the same as product invention.